Thanks Trding! I agree with your response and know the role of leronlimab is to make CCR5 metastatic cancers a chronic disease.

I just found that excerpt from the patent intriguing when used as “concomitant treatment” and the word “abated.” I just looked up the official definition of abated and agree that it is most synonymous with remission and not cure.

It also makes sense that CTC test will be checked more frequently even during remission....with tightly monitored threshold variables. If leronlimab works as expected, as a patient I definitely would not want to stop taking it after remission, etc. I’m curious how insurance would view this? At what price point is a preventive medicine worth the cost from their perspective (it’s sad this even has to be determined, but to them it is simply a business/financial decision).

I don’t want to get too optimistic on cancer expectations, so just crossing fingers for positive results!